Existing investors Boehringer Ingelheim Venture Fund (BIVF) and Parkwalk Advisors have lead a GBP16 million Series B funding round in Brainomix, an AI-powered medtech solutions company.
New investor, Tencent Holdings, also participated in the round along with the Oxford University Innovation Fund (OUIF), with the investment set to be used to fund the company’s expansion into new markets and new therapeutic indications, including lung fibrosis and cancer.
